NEXT GENERATION INVESTMENT BANKING

Members network
Limited Mobile Version
KAN

Kancera

Today
Day High
3.09
3.07
Day Low
3.01
Day Open
3.09
Prev Close
3.01
VWAP
3.1
Volume
277K
Turnover
0.847M
Top Broker
VWAP
2.9
Avg Volume
320K
Avg Turnover
0.942M
Top Brokers
AVA/NON
VWAP
2.9
Avg Volume
309K
Avg Turnover
0.901M
Top Brokers
AVA/NON
VWAP
2.9
Avg Volume
269K
Avg Turnover
0.774M
Top Brokers
AVA/NON
52 week summary
Price Range
2.4
Last
4.2
Beta
N/A
Market Cap
403.7M
Total Return
-18.8%
Trailing P/E
N/A
Div Yield
N/A%
Shares Outstanding
131.5M
Next Earnings Date
19 May
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months 5.9%
Change 12 Months -29.0%
Volume Trend
Average Volume 10 vs 60 Days 25.3%
Price VS
52 Week High -26.3%
50 Day Moving Average 12.1%
200 Day moving Average 9.4%

Add article markers

Compare Kancera to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Thomas Olin, CEO
  • Executive board
  • Erik Nerpin, Chairman of the board
Source: Millistream
Major Owners Equity Votes
Avanza Pension 10.3%
10.3%
CBNY-CHARLES SCHWAB FBO CUSTOMER CITIBANK NA 3.5%
3.5%
Nordnet Pensionsförsäkring 3.5%
3.5%
Bertil Lindkvist 3.4%
3.4%
Marianne Rapp 2.9%
2.9%
Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Source: Redeye
Source: Redeye

Peer Group

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.


Spago Nanomedicalicon-close

Redeye Rating

6.0
6.0
5.5
0.0
0.0
Bioinvent Internationalicon-close

Redeye Rating

6.0
5.0
5.5
0.0
1.0
Hansa Medicalicon-close

Redeye Rating

8.0
9.0
6.5
0.0
1.0
Sanionaicon-close

Redeye Rating

7.0
6.0
5.5
0.0
1.0
Sprint Bioscienceicon-close

Redeye Rating

Sprint Bioscience is not rated

WntResearch icon-close

Redeye Rating

WntResearch is not rated